PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Allopurinol

Drugs in development · updated 30 October 2026

Allopurinol: clinical trials and development status

Other names and codes: Aloprim, Lopurin

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 23 August 2018

As of 30 October 2026 Allopurinol is in 9 active clinical trials (recruiting or ongoing, phases I–III) for 23 diseases. The most advanced phase is III.

9Active trials
IIIMost advanced phase
23Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Allopurinol and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Burkitt lymphomaIII2NCT03150693
GoutIII2NCT07089875
HyperuricemiaIII2NCT07089888
Brain hypoxia-ischemiaIII1NCT04217421
Brain InjuriesIII1NCT04217421
Cardiovascular diseaseIII1NCT05943821
Congenital heart diseaseIII1NCT04217421
DepressionII–III1NCT07574060
Acute biphenotypic leukaemiaII1NCT05805605
Acute myeloid leukemiaII1NCT05805605
Chronic lymphocytic leukemiaII1NCT05805605
Follicular lymphomaII1NCT05805605
LeukemiaII1NCT05536349
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveII1NCT05805605
Lymphoma, B-Cell, Marginal ZoneII1NCT05805605
Myelodysplastic SyndromesII1NCT05805605
MyelofibrosisII1NCT05805605
Myeloid leukemiaII1NCT05805605
Myeloproliferative disordersII1NCT05805605
Plasma cell leukemiaII1NCT05805605
Precursor lymphoblastic lymphoma/leukemiaII1NCT05805605
Prolymphocytic leukemiaII1NCT05805605
T-cell lymphomaII1NCT05805605

Everything on Allopurinol

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch